202752-04-3

Basic information

• Product Name: 4'-METHOXY[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE
• Synonyms: 4'-METHOXY[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE;4'-METHOXY-BIPHENYL-4-SULFONYL CHLORIDE;[4-(4-METHOXYPHENYL)PHENYL]SULFONYL CHLORIDE;[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE, 4'-METHOXY-;BUTTPARK 99\57-75;4-(4-Methoxyphenyl)benzenesulfonyl chloride;4'-Methoxybiphenyl-4-sulfonyl chloride 95%
• CAS NO: 202752-04-3
• Molecular Formula: C₁₃H₁₁ClO₃S
• Molecular Weight: 282.74
• Mol File: 202752-04-3.mol
• Article Data: 2

Chemical Properties

• Melting Point: 103 °C
• Boiling Point: 409.3 °C at 760 mmHg
• Flash Point: 201.3 °C
• Appearance: /
• Density: 1.312 g/cm³
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 4'-METHOXY[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-METHOXY[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE(202752-04-3)
• EPA Substance Registry System: 4'-METHOXY[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE(202752-04-3)

Safety Data

• Hazard Codes: C
• Statements: 14-34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8 / PGII
• WGK Germany: 3
• HazardClass: 8
• Hazardous Substances Data: 202752-04-3(Hazardous Substances Data)

Usage

General Description

4'-Methoxy[1,1'-biphenyl]-4-sulfonyl chloride is a specific chemical compound with the molecular formula C13H11ClO3S. It is a sulfonyl chloride derivative, which contains a sulfone functional group. 4'-METHOXY[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE is widely used in organic synthesis and pharmaceutical manufacturing as a reactive intermediate in the production of various chemicals and drugs. The 4'-methoxy substituted biphenyl sulfonyl chloride is commonly used in the creation of sulfonamide-based pharmaceuticals and as a reagent in the synthesis of organic compounds. It is also used as a building block in the production of specialty chemicals and agrochemicals. Furthermore, this compound can also be employed in the development of materials for electronic and optical applications due to its unique chemical properties.

Upstream product

• 256439-82-4 4-(4-methoxyphenyl)-phenylsulfonic acid 

Downstream Products

• 369656-86-0 Methyl (R)-N-{[4'-Methoxy-(1,1'-biphenyl)-4-yl]-sulfonyl}-amino-(4-hydroxy-cyclohex-1-yl)-acetate 
• 586377-20-0 Methyl (1,4-dioxa-spiro[4.5]dec-8-yl)-N-{[4'-Methoxy-(1,1'-biphenyl)-4-yl]-sulfonyl}-amino-acetate 
• 1609109-81-0 NXT₉₆₉ 
• 1440967-66-7 C₂₅H₂₄N₂O₅S 
• 1329465-13-5 C₂₄H₂₂N₂O₅S 
• 1232008-16-0 C₂₆H₂₁N₃O₃S 
• 1232007-45-2 4'-methoxy-N-(quinolin-8-yl)biphenyl-4-sulfonamide 
• 1161343-30-1 N-(2-(benzo[d]thiazol-2-yl)phenyl)-4'-methoxybiphenyl-4-sulfonamide 
• 1161343-26-5 N-(2-(benzo[d]thiazol-2-yl)ethyl)-4'-methoxybiphenyl-4-sulfonamide 
• 1161342-48-8 N-(3-(benzo[d]thiazol-2-yl)isoxazol-5-yl)-4'-methoxybiphenyl-4-sulfonamide 
• 1161343-14-1 N-(benzo[d]thiazol-2-yl)-4'-methoxybiphenyl-4-sulfonamide 
• 334991-59-2 (2R,3S)-4-Benzyloxy-3-hydroxy-2-(4'-methoxy-biphenyl-4-sulfonylamino)-butyric acid 

Relevant articles and documents

Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13

The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis. Our efforts have resulted in the discovery of a series of carboxylic acid inhibitors of MMP-13 that do not significantly inhibit the related MMP-1 (collagenase-1) or tumor necrosis factor-α (TNF-α) converting enzyme (TACE). It has previously been suggested (but not proven) that inhibition of the latter two enzymes could lead to side effects. A promising carboxylic acid lead 9 was identified and a convergent synthesis developed. This paper describes the optimization of 9 and the identification of a compound 24f for further development. Compound 24f is a subnanomolar inhibitor of MMP-13 (IC50 value 0.5 nM and Ki of 0.19 nM) having no activity against MMP-1 or TACE (IC50 of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 24f significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p 0.05) and at 10 mg/kg (40% inhibition, p 0.05).